NCT04075032 is a NA clinical trial of Pomegranate extract in Metabolic Syndrome, sponsored by National Research Council, Spain.

Who is sponsoring NCT04075032?

NCT04075032 is sponsored by National Research Council, Spain.

What drugs are being tested in NCT04075032?

Interventions in NCT04075032: Pomegranate extract, Placebo.

What condition does NCT04075032 study?

NCT04075032 studies Metabolic Syndrome.

Is NCT04075032 still recruiting?

NCT04075032 is currently completed. Last updated 10 September 2020.

Last reviewed 2020-09-10 · How we verify

NCT04075032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pomegranate Consumption by Poly-medicated Metabolic Syndrome Patients

Completed NA Last updated 10 September 2020

What this trial tests

NA trial testing Pomegranate extract in Metabolic Syndrome in 60 participants. Completed in 31 December 2019.

Timeline

10 June 2018

Primary endpoint
21 July 2019

31 December 2019

Quick facts

Lead sponsor	National Research Council, Spain
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	10 June 2018
Primary completion	21 July 2019
Estimated completion	31 December 2019
Sites	1 location across Spain

Drugs / interventions tested

Pomegranate extract
Placebo

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

National Research Council, Spain

Who can join

18 and older, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate whether the medication in polymedicated metabolic syndrome patients could determine the effects of a pomegranate extract on i) metabolic markers, ii) inflammatory markers, and iii) the modulation of the gut microbiota.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Proanthocyanidins: Impact on Gut Microbiota and Intestinal Action Mechanisms in the Prevention and Treatment of Metabolic Syndrome.
Redondo-Castillejo R, Garcimartín A, Hernández-Martín M, López-Oliva ME, et al · · 2023 · cited 19× · PMID 36982444 · DOI 10.3390/ijms24065369
There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication.
Cortés-Martín A, Iglesias-Aguirre CE, Meoro A, Selma MV, et al · · 2020 · cited 18× · PMID 32183480 · DOI 10.3390/microorganisms8030416
Human gut microbiome: Therapeutic opportunities for metabolic syndrome-Hype or hope?
Horvath A, Zukauskaite K, Hazia O, Balazs I, et al · · 2024 · cited 15× · PMID 37771199 · DOI 10.1002/edm2.436

Verify or expand the search:

Other trials of Pomegranate extract

Trials testing the same drug.

NCT05588479 — Pomegranate Extract and Inflammageing · NA · completed

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Other National Research Council, Spain trials

Trials by the same sponsor.

NCT07508735 — Bioavailability of Phlorotannins and Carotenoids Following the Intake of Crackers Fortified With Seaweed · NA · active not recruiting
NCT06735222 — Bioavailability of Hydroxytyrosol in Humans Co-administered With EPA · NA · completed
NCT07182370 — Polyphenol Metabolism and Personalized Nutrition in Menopause (PolyPause). · NA · active not recruiting
NCT06295913 — Hydroxytyrosol Dietary Supplement and Prevention of Age-Related Diseases · NA · completed
NCT04383639 — Cocoa/Carob Polyphenols and Postprandial Changes in Type 2 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04075032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Research Council, Spain
Last refreshed: 10 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04075032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing